Findings support link between hsCRP, macular degeneration

Findings support link between hsCRP, macular degeneration
Pooled results from five cohorts confirm that high levels of high-sensitivity C-reactive protein correlate with increased future risk of age-related macular degeneration, according to research published online Feb. 7 in JAMA Ophthalmology.

(HealthDay)—Pooled results from five cohorts confirm that high levels of high-sensitivity C-reactive protein (hsCRP) correlate with increased future risk of age-related macular degeneration (AMD), according to research published online Feb. 7 in JAMA Ophthalmology.

Vinod P. Mitta, M.D., M.P.H., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues conducted a pooled analysis of prospective nested case-control data from five cohorts to examine the correlation between hsCRP and the risk of AMD in U.S. men and women. A total of 647 incident cases of AMD were identified and matched with controls (two controls for each case of dry AMD and three for each case of neovascular AMD).

After adjustment for smoking status, the researchers found that the cohort-specific odds ratios for incident AMD for participants with high (>3 mg/L) versus low (<1 mg/L) hsCRP levels ranged from 0.94 (95 percent confidence interval [CI], 0.58 to 1.51) to 2.59 (95 percent CI, 0.58 to 11.67). After heterogeneity testing, pooled findings across the cohorts showed that there was a significantly increased risk of incident AMD for those with high versus low hsCRP levels (odds ratio, 1.49). Those with high hsCRP levels also had a significantly increased risk of neovascular AMD (odds ratio, 1.84).

"Overall, these pooled findings from five prospective cohorts add further evidence that elevated levels of hsCRP predict greater future risk of AMD," the authors write. "This information might shed light on underlying mechanisms and could be of clinical utility in the identification of persons at high risk of AMD who may benefit from increased adherence to lifestyle recommendations, schedules, and therapeutic protocols."

One author is a co-inventor on patents relating to the use of inflammatory in and diabetes that have been licensed to and Siemens.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Genotyping IDs long-term risk of macular degeneration

Nov 13, 2012

(HealthDay)—Genotyping of two genetic risk alleles can be used to estimate the long-term risk of early and late age-related macular degeneration (AMD), but knowing the phenotype is important in assessing ...

Recommended for you

New glaucoma culprit is found

16 hours ago

Glaucoma, a leading cause of irreversible blindness, is associated with elevated pressure in the eye. This elevated pressure essentially is due to a plumbing problem. Fluid builds up in the eye, increasing ...

New glaucoma cause discovered

Sep 09, 2014

Northwestern Medicine scientists have discovered a novel cause of glaucoma in an animal model, and related to their findings, are now developing an eye drop aimed at curing the disease. They believe their ...

Mouse studies advance treatment for common eye diseases

Sep 03, 2014

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development ...

User comments